Related Experiment Video
Updated: Mar 13, 2026
10:39
Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy
Published on: April 16, 2019
8.2K
Peripheral killer cells do not differentiate between asthma patients with or without fixed airway obstruction
Carolyn Tubby1, Ola H Negm1,2, Timothy Harrison3
1a School of Life Sciences, University of Nottingham , Nottingham , UK.
Summary
Peripheral killer cell numbers and functions do not differ between asthma patients with or without fixed airway obstruction (FAO), suggesting these cells do not distinguish between asthma subtypes.
Area of Science:
- Immunology
- Respiratory Medicine
Background:
- Killer cells (CD8+ T cells, NK cells, NKT cells) are implicated in asthma and COPD.
- The role of killer cells in asthma with fixed airway obstruction (FAO) remains unclear.
Purpose of the Study:
- To investigate killer cell numbers, phenotype, and function in asthma patients with and without FAO, compared to healthy individuals.
Main Methods:
- Analyzed peripheral CD8+ T cells, NK cells, and NKT-like cells in 14 asthma patients with FAO, 7 without FAO, and 9 healthy controls.
- Assessed cell numbers, receptor expression, MAPK signaling, cytotoxic mediators, and functional cytotoxicity.
Main Results:
- No significant differences observed in killer cell numbers between groups.
- Receptor expression, signaling molecule expression, and cytotoxic mediator expression were similar across all groups.
- Functional cytotoxicity of peripheral killer cells did not differ between asthma patients with FAO, asthma patients without FAO, and healthy individuals.
Conclusions:
- Peripheral killer cell numbers and functions do not differentiate asthma patients with or without fixed airway obstruction.
- These findings suggest killer cells do not play a distinct role in distinguishing asthma subtypes with varying degrees of airway obstruction.
Keywords:
CD8+ T cellsasthmafixed airflow obstructionnatural killer T cellsnatural killer cellsprotein lysate microarrayMore Related Videos
Related Concept Videos
01:26Asthma-II: Pathophysiology and Classification
4.8K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.8K
01:20Asthma: Pathogenesis and Management
1.5K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.5K
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
2.2K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.2K
01:30Asthma-IV: Diagnostic and Management
3.3K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.3K
01:29Asthma-I: Introduction
3.7K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
3.7K
01:19Antiasthma Drugs: Leukotriene Modifiers
2.1K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
2.1K